![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Lu, Yen-Shen; Im, Seock-Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Cardoso, Fatima; Harbeck, Nadia; Hurvitz, Sara; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; De Laurentiis, Michelino; Im, Young-Hyuck; Kuemmel, Sherko; El-Saghir, Nagi; O'Regan, Ruth; Gasch, Claudia; Solovieff, Nadia; Wang, Craig; Wang, Yongyu; Chakravartty, Arunava; Ji, Yan und Tripathy, Debu
(2022):
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
In: Clinical Cancer Research, Bd. 28, Nr. 5: S. 851-859
Bardia, Aditya; Su, Fei; Solovieff, Nadia; Im, Seock-Ah; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Jung, Kyung Hae; Colleoni, Marco; Villanueva Vazquez, Rafael; Franke, Fabio; Hurvitz, Sara; Harbeck, Nadia; Chow, Louis; Taran, Tetiana; Lorenc, Karen Rodriguez; Babbar, Naveen; Tripathy, Debu und Lu, Yen-Shen
(2021):
Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
In: Jco Precision Oncology, Bd. 5: S. 1408-1420
Tripathy, Debu; Im, Seock-Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Harbeck, Nadia; Hurvitz, Sara A.; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; Laurentiis, Michelino de; Im, Young-Hyuck; Kümmel, Sherko; El-Saghir, Nagi; Liu, Mei-Ching; Carlson, Gary; Hughes, Gareth; Diaz-Padilla, Ivan; Germa, Caroline; Hirawat, Samit und Lu, Yen-Shen
(2018):
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
In: Lancet Oncology, Bd. 19, Nr. 7: S. 904-915